Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.48 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 7/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | FABP4 | P15090 | 3/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4963682 | 1.00 | HSD11B1 (0.48) | HSD11B1HSD17B2MTNR1AMTNR1BMAPT | |
| SCHEMBL4516092 | 0.89 | HSD11B1 (0.52) | HSD11B1HSD17B2MTNR1AMTNR1BMAPT | |
| SCHEMBL4510840 | 0.86 | HSD11B1 (0.48) | HSD11B1HSD17B2MTNR1AMTNR1BMAPT | |
| SCHEMBL13889113 | 0.86 | CA1 (0.50) | HSD11B1HSD17B2MTNR1AMTNR1BMAPT | |
| SCHEMBL4524976 | 0.85 | HSD11B1 (0.47) | HSD11B1HSD17B2FABP4HTR6QRFPR | |
| SCHEMBL4505977 | 0.84 | HSD11B1 (0.52) | HSD11B1HSD17B2MTNR1AMTNR1BMAPT | |
| SCHEMBL4522178 | 0.83 | HTR6 (0.64) | MTNR1AMTNR1BMAPTCYP2C9CYP1A2 | |
| SCHEMBL4519498 | 0.80 | HTR6 (0.55) | HSD11B1HSD17B2MTNR1AMTNR1BMAPT | |
| SCHEMBL4961886 | 0.78 | ADRA1A (0.57) | HSD11B1HSD17B2MAPTCYP2C9FABP4 | |
| SCHEMBL4508627 | 0.78 | ADRA1A (0.57) | HSD11B1HSD17B2MAPTCYP2C9FABP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099187-A1 | Novel 8-Sulfonyl-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5HT6 Receptor | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| US-20090099187-A1 | Novel 8-Sulfonyl-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5HT6 Receptor | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| US-20090099187-A1 | Novel 8-Sulfonyl-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5HT6 Receptor | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| EP-1888518-A1 | NOVEL 8-SULFONYL-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR | AstraZeneca AB (SE) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006126938-A1 | NOVEL 8-SULFONYL-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099187-A1 | Novel 8-Sulfonyl-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5HT6 Receptor | HTR6, HTR1D, HTR1A | HSD11B1 2184/4885HSD17B2 2494/4885MTNR1A 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.